• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

    58.86 +18.06 (+44.26%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,318,189
    Open 54.93
    Bid (Size) 59.00 (300)
    Ask (Size) 59.50 (200)
    Prev. Close 40.80
    Today's Range 53.01 - 59.79
    52wk Range 14.27 - 59.79
    Shares Outstanding 25,688,062
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    Why Eton Pharmaceuticals Is Top of the Class Today ↗
    Eton's cure for an expensive valuation: a 99% sales growth rate. 
    Via The Motley Fool

    Performance

    YTD
    +262.0%
    +262.0%
    1 Month
    +52.9%
    +52.9%
    3 Month
    +94.5%
    +94.5%
    6 Month
    +244.8%
    +244.8%
    1 Year
    +252.5%
    +252.5%

    More News

    Read More
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    Eton Pharmaceuticals (NASDAQ:ETON) Soars on Q1 Beat, Raises Full-Year Guidance ↗
    Via Chartmill
    Eton Pharmaceuticals (NASDAQ:ETON) Posts Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
    Via Chartmill
    Discover the top movers in Friday's pre-market session. ↗
    Via Chartmill
    News headline image
    Eton Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript ↗
    Via Benzinga
    Topics Earnings
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton (ETON) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Eton Pharmaceuticals Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharmaceuticals Announces CFO Succession Plan
    From Eton Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Eton Pharma (ETON) Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
    From Eton Pharmaceuticals
    Via GlobeNewswire

    Frequently Asked Questions

    Is Eton Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Eton Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Eton Pharmaceuticals, Inc. - Common Stock trade on?
    Eton Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock is ETON on the Nasdaq Stock Market
    What is the current price of Eton Pharmaceuticals, Inc. - Common Stock?
    The current price of Eton Pharmaceuticals, Inc. - Common Stock is 58.86
    When was Eton Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Eton Pharmaceuticals, Inc. - Common Stock was at 08/14/26 04:00 PM ET
    What is the market capitalization of Eton Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Eton Pharmaceuticals, Inc. - Common Stock is 1.51B
    How many shares of Eton Pharmaceuticals, Inc. - Common Stock are outstanding?
    Eton Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.